mercaptopurine and Glaucoma

mercaptopurine has been researched along with Glaucoma* in 1 studies

Other Studies

1 other study(ies) available for mercaptopurine and Glaucoma

ArticleYear
In vitro release of hydrophobic drugs from polyanhydride disks.
    Ophthalmic surgery, 1991, Volume: 22, Issue:11

    We have evaluated the feasibility of using polyanhydride disks containing hydrophobic antiproliferative agents for controlled drug release after glaucoma filtration surgery. Taxol and VP-16 were the most potent inhibitors of fibroblast proliferation tested, with ID50s of 3 ng/mL and 200 ng/mL, respectively. In vitro release of taxol occurred at concentrations exceeding its ID50 for at least 100 days; VP-16 was released for 31 days. The media into which the drugs were released were able to inhibit fibroblast proliferation in vitro, indicating that the bioactivity of the drugs withstood incorporation into, and release from, the polyanhydride. Polyanhydride disks containing taxol and VP-16 merit testing in animal models of glaucoma filtration surgery.

    Topics: Alkaloids; Cell Division; Cells, Cultured; Decanoic Acids; Delayed-Action Preparations; Dicarboxylic Acids; Drug Implants; Etoposide; Fibroblasts; Floxuridine; Fluorouracil; Glaucoma; Humans; Mercaptopurine; Paclitaxel; Polymers; Postoperative Complications; Vincristine

1991